Ryan K. McBain, PhD, MPH; Jonathan Cantor, PhD; Megan F. Pera, MS; et al.
open access
has audio
JAMA Health Forum. 2023;4(1):e224936. doi:10.1001/jamahealthforum.2022.4936
This cohort study examines changes in use of in-person and telehealth mental health services among commercially insured adults across all 50 US states during the first year of the COVID-19 pandemic.
-
Podcast:
Use of Mental Health Services During the COVID-19 Pandemic
Lisa Clemans-Cope, PhD; Marni Epstein, BA; Jessica Banthin, PhD; et al.
open access
JAMA Health Forum. 2023;4(1):e225012. doi:10.1001/jamahealthforum.2022.5012
This cross-sectional study considers 18 top-selling drugs to demonstrate a new approach to improved estimation of Medicaid rebates to better understand trends in Medicaid and non-Medicaid spending and drug pricing.
Daniel T. Myran, MD, MPH; Peter Tanuseputro, MD, MHSc; Nathalie Auger, MD, MHSc; et al.
open access
JAMA Health Forum. 2023;4(1):e225041. doi:10.1001/jamahealthforum.2022.5041
This cross-sectional study uses population data to evaluate the association of pediatric hospitalizations for cannabis poisoning with legalization of edible cannabis products in Canada.
Patricia C. Dykes, PhD, MA, RN; Mica Curtin-Bowen, BA; Stuart Lipsitz, ScD; et al.
open access
JAMA Health Forum. 2023;4(1):e225125. doi:10.1001/jamahealthforum.2022.5125
This economic evaluation reports on the costs of inpatient falls and the cost savings associated with implementation of an evidence-based fall prevention program.
Benjamin N. Rome, MD, MPH; Sarosh Nagar; Alexander C. Egilman, BA; et al.
open access
JAMA Health Forum. 2023;4(1):e225218. doi:10.1001/jamahealthforum.2022.5218
This cross-sectional study uses a policy simulation analysis to assess how much Medicare price negotiation would have reduced prescription drug spending if the Inflation Reduction Act of 2022 had been effective from 2018 to 2020.